Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer
To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients. The systems pathology approach applied allows a precise quantification of the marker express...
| Autores: | , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:226330 |
| Acceso en línea: | https://ddd.uab.cat/record/226330 https://dx.doi.org/urn:doi:10.1186/s13104-019-4100-z |
| Access Level: | acceso abierto |
| Palabra clave: | Active β-catenin HLA class1 Wnt/β-catenin pathway Prostate cancer Systems pathology |
| Sumario: | To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients. The systems pathology approach applied allows a precise quantification of the marker expression in the different cell compartments as well as the determination of the areas that coexpress two markers. Our data shows that the accumulation of β-catenin in the nuclear compartment is significantly decreased in the adjacent normal areas when compared to tumor of the same patients (p < 0.001). In conclusion, the application of this novel multiple immunofluorescence assay demonstrates that the upregulation of Active β-catenin is a relatively common feature of prostate tumor development, and further supports the activation of the Wnt/β-catenin pathway in prostate cancer progression. The online version of this article (10.1186/s13104-019-4100-z) contains supplementary material, which is available to authorized users. |
|---|